HKB99 是磷酸甘油酸突变酶 1(PGAM1)的变构抑制剂,可诱导细胞凋亡(apoptosis),抑制细胞侵袭性伪足的形成及迁移,增加氧化应激,激活 JNK/c-Jun,并抑制 AKT 和 ERK,可用于非小细胞肺癌(NSCLC)的研究。
产品编号: MS-T20739 纯度: 99.65% CAS No.: 2414908-90-8 分子式: C23H18N2O6S 分子量: 450.46
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

HKB99 是磷酸甘油酸突变酶 1(PGAM1)的变构抑制剂,可诱导细胞凋亡(apoptosis),抑制细胞侵袭性伪足的形成及迁移,增加氧化应激,激活 JNK/c-Jun,并抑制 AKT 和 ERK,可用于非小细胞肺癌(NSCLC)的研究。

生物实验数据

生物活性 HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1) that induces apoptosis, inhibits the formation of invadopodia and cell migration, increases oxidative stress, activates JNK/c-Jun, and inhibits AKT and ERK, and can be used for research on non-small cell lung cancer (NSCLC).
体外研究
(In Vitro)

HKB99 (1-5 μM,6 小时) 可抑制侵袭性伪足形成,并上调 Erlotinib (MS-W28270) 耐药的非小细胞肺癌细胞 (NSCLC) 中的 PAI-2。
HKB99 (72 小时) 以浓度依赖性方式显著抑制 NSCLC 细胞 (PC9、HCC827、H1975 和 A549) 的增殖,IC50 值分别为 0.79、1.22、1.34、5.62 μM。
HKB99 (1-5 μM,6 小时) 可抑制 NSCLC 细胞 PGAM1 和 ACTA2 的相互作用,破坏细胞迁移。
HKB99 (1-5 μM,6-48 小时) 通过激活 JNK/cJun 信号通路诱导 NSCLC 细胞中 ROS 依赖性细胞凋亡,(0.1-10 μM,72 小时) 且在获得性 Erlotinib (MS-W28270) 耐药的 HCC827ER 细胞中诱导的细胞凋亡高于其亲本 HCC827 细胞。

Cell Viability Assay

Cell Line: HCC827 and HCC827ER cells
Concentration: 0.1-10 μM
Incubation Time: 72 h
Result: Preferentially suppresses cellular proliferation in acquired Erlotinib (MS-W28270)-resistant HCC827ER cells, and it has higher potency (IC50 value of 1.020 μM) and efficacy than is achieved in the parental HCC827 cells (IC50 value of 1.705 μM).

Cell Migration Assay

Cell Line: PC9, HCC827, HCC827ER9 cells
Concentration: 0.2, 0.4, 5 μM
Incubation Time: 3, 20 h
Result: Quickly disrupted the invadopodia-like structures at 0.4 μM in HCC827ER9 cells.
The level of F-actin was significantly decreased at 5 μM in HCC827ER9 cells.
Completely ablated cell migration of PC9 and HCC827 cells in 20 h.

Apoptosis Analysis

Cell Line: PC9, 16HBE, HCC827
Concentration: 0.5, 1, 5 μM
Incubation Time: 24 h
Result: Caused remarkable apoptosis with fraction from 5% to 28% in PC9.
No apoptosis was stimulated under the same condition in 16HBE cells.
Consistently induced apoptosis in HCC827 cells

Western Blot Analysis

Cell Line: HCC827 and HCC827ER cells
Concentration: 1, 5 μM (HCC827), 1.25, 2.5μM (HCC827ER)
Incubation Time: 6 h
Result: Notably increased the level of PAI-2 at a low concentration of 1.25 μM in HCC827ER.
Increased the level of PAI-2 at 5 μM in HCC827.

Western Blot Analysis

Cell Line: HCC827 and HCC827ER cells
Concentration: 5 μM (HCC827), 1, 5μM (HCC827ER)
Incubation Time: 6 h
Result: Inhibited the interaction of PGAM1 with ACTA2, while no difference was observed in the total amount of ACTA2
体内研究
(In Vivo)

HKB99 (35-100 mg/kg;腹腔注射;每日一次或每 3 天一次) 显著抑制肿瘤生长,并增强 Erlotinib 在小鼠异种移植瘤中的杀瘤作用。HKB99 可抑制静脉注射非小细胞肺癌细胞后的肿瘤转移。

Animal Model: Female BALB/c nu/nu mice (4 weeks) (NSCLC cells were injected subcutaneously on two sites per mouse) or (HCC827-Luc and HCC827ER9-Luc cells about 5 x 106 were injected through the tail vein injection)
Dosage: 35, 100 mg/kg
Administration: Intraperitoneal injection (i.p.); daily or once every 3 days
Result: Attenuated tumor growth of PC9 xenografts in a murine subcutaneous model.
The T/C ratio was 32.97%, while tumors in combination with Erlotinib were almost completely abrogated (T/C ratio of 9.46%) in PC9 xenografts.
Induced much tumor necrosis in the PC9 xenografts.
Tumor weight was relevantly regressed in PC9 xenografts.
Combination with Erlotinib caused complete ablation of the tumors in HCC827 xenografts.
Significantly inhibited the HCC827ER9 xenografts’ growth with a T/C ratio of 34.76%.
Ablated the massive colonization and metastasis foci of HCC827-Luc and HCC827ER9-Luc, while the control group showed areas of high fluorescence, representing tumor foci, mainly in the lungs and abdominal organs.
The average bioluminescence intensity did not increase.
No death or weight loss over 10% was documented, indicating no subacute toxicity.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 450.46
分子式 C23H18N2O6S
CAS No. 2414908-90-8

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (277.49 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2200 mL11.0998 mL22.1995 mL55.4988 mL
5 mM0.4440 mL2.2200 mL4.4399 mL11.0998 mL
10 mM0.2220 mL1.1100 mL2.2200 mL5.5499 mL
15 mM0.1480 mL0.7400 mL1.4800 mL3.6999 mL
20 mM0.1110 mL0.5550 mL1.1100 mL2.7749 mL
25 mM0.0888 mL0.4440 mL0.8880 mL2.2200 mL
30 mM0.0740 mL0.3700 mL0.7400 mL1.8500 mL
40 mM0.0555 mL0.2775 mL0.5550 mL1.3875 mL
50 mM0.0444 mL0.2220 mL0.4440 mL1.1100 mL
60 mM0.0370 mL0.1850 mL0.3700 mL0.9250 mL
80 mM0.0277 mL0.1387 mL0.2775 mL0.6937 mL
100 mM0.0222 mL0.1110 mL0.2220 mL0.5550 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础